Cintia Costi

Cintia Costi

Auto-generated profile, based on publicly available information

Cintia Costi

Secretaria Estadual da Saúde do Rio Grande do Sul, Brasil

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2005 in Journal of Infection
Verified
Journal Article
Closed access
CSC.M.D. Silva
C.M.D. Silva
CCC. Costi
C. Costi
CCC. Costa
C. Costa
CMC. Michelon
C. Michelon
ROR. Oravec
R. Oravec
MRM.L. Rossetti
M.L. Rossetti

31 August 2007 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
CSCláudia Maria Dornelles da Silva
Cláudia Maria Dornelles da Silva
CCCintia Costi
Cintia Costi
LKLuciano Percival Krug
Luciano Percival Krug
ARAna Beatris Ramos
Ana Beatris Ramos
TGTarciana Grandi
Tarciana Grandi
MRMaria Lucia Rosa Rossetti
Maria Lucia Rosa Rossetti
Hepatitis C virus (HCV) isolates have been divided into six genotypes (1 to 6). The duration of hepatitis C standard treatment is 48 weeks for patients infected with HCV genotype 1 vs 24 weeks for those infected with genotypes 2 and 3. A total of 1544 HCV isolates from chronic patients living in the southern Brazilian states of Rio Grande do Sul (RS, n = 627) and Santa Catarina (SC, n = 917) were genotyped by restriction fragment length polymorphism (RFLP) of polymerase chain reaction (PCR) products. In RS, 338 (53.9%; 95% CI 50.0 - 57.8%), 34 (5.4%; 95% CI 3.8 - 7.4%) and, 255 (40.7%; 95% CI 36.9 - 44.6%) samples were from genotypes 1, 2, and 3, respectively. In SC, 468 (51%; 95% CI 47.8 - 54.2%), 26 (2.9%; 95% CI 1.9 - 4.1%) and, 423 (46.1%; 95% CI 42.9 - 49.3%) samples were from genotypes 1, 2, and 3, respectively. Genotyping results were confirmed by direct nucleotide sequencing of PCR products derived from 68 samples, without any discrepancy between PCR-RFLP and nucleotide sequencing methods. In conclusion, almost half of the hepatitis C patients from South of Brazil are infected by genotypes 2 and 3 and, these results have important consequential therapeutic implications as they can be treated for only 24 weeks, not 48.

14 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CGCarolina Souza Gusatti
Carolina Souza Gusatti
CCCintia Costi
Cintia Costi
MHMaria Laura Halon
Maria Laura Halon
TGTarciana Grandi
Tarciana Grandi
AMArlete Ferrari Rech Medeiros
Arlete Ferrari Rech Medeiros
MRMaria Lucia Rosa Rossetti
Maria Lucia Rosa Rossetti
Hepatitis B virus genotype A1 (HBV/A1), of African origin, is the most prevalent genotype in Brazil, while HBV/F predominates in the other South American countries. However, HBV/D is the most common in the three states of southern Brazil, where ‘islands’ of elevated prevalence, as Chapecó and other cities, have been described. In this study, 202 HBV chronic carriers attending in 2013 the viral hepatitis ambulatory of Chapecó, were investigated. In comparison with previous studies performed in the same ambulatory, a rapid aging of the HBV infected population was observed (mean age of the newly diagnosed patients increasing from 29.9 ± 10.3 years in 1996 to 44.4 ± 13.3 years in 2013), probably due to a singular vaccination schedule at Chapecó that included not only children but also adolescents. Phylogenetic and BLAST analyses (S region) classified 91 HBV isolates into genotypes A (n = 3) and D (n = 88). The majority of HBV/D isolates were closely related to D3 sequences. To understand the reasons for the absence or near absence of genotypes A and F, and how HBV/D was introduced in the south of Brazil, HBV/D infected patients were inquired about their genealogical and geographical origins. Forty-three (52%) patients have their four grandparents of Italian origin, vs. seven (8%) who have their four grandparents of Brazilian origin. At all, 65 out of 83 (78%) patients had at least one grandparent originating from Italy. Taking into consideration the fact that Italy is one of the few countries where subgenotype D3 is predominant, the results strongly suggested that HBV/D was introduced in Brazil through Italian immigration which culminated between 1870 and 1920.

9 March 2016 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
CGCarolina de Souza Gusatti
Carolina de Souza Gusatti
CCCintia Costi
Cintia Costi
RMRúbia Marília de Medeiros
Rúbia Marília de Medeiros
MHMaria Laura Halon
Maria Laura Halon
TGTarciana Grandi
Tarciana Grandi
MRMaria Lucia Rosa Rossetti
Maria Lucia Rosa Rossetti

1 March 2009 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
FCFernanda Goulart Lanes Chula
Fernanda Goulart Lanes Chula
RRRodrigo Rodenbusch
Rodrigo Rodenbusch
SSSimone Schumacher
Simone Schumacher
TGTarciana Grandi
Tarciana Grandi
CMCandice Tosi Michelon
Candice Tosi Michelon
CSCláudia Maria Dornelles da Silva
Cláudia Maria Dornelles da Silva

1 June 2014 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
TGTarciana Grandi
Tarciana Grandi
CSCláudia Maria Dornelles da Silva
Cláudia Maria Dornelles da Silva
KAKarine Medeiros Amaral
Karine Medeiros Amaral
PPPaulo Dornelles Picon
Paulo Dornelles Picon
CCCintia Costi
Cintia Costi
MRMaria Lucia Rosa Rossetti
Maria Lucia Rosa Rossetti
Certain host single nucleotide polymorphisms (SNPs) affect the likelihood of a sustained virological response (SVR) to treatment in subjects infected with hepatitis C virus (HCV). SNPs in the promoters of interleukin (IL)-10 (-1082 A/G, rs1800896), myxovirus resistance protein 1 (-123 C/A, rs17000900 and -88 G/T, rs2071430) and tumour necrosis factor (TNF) (-308 G/A, rs1800629 and -238 G/A, rs361525) genes and the outcome of PEGylated α-interferon plus ribavirin therapy were investigated. This analysis was performed in 114 Brazilian, HCV genotype 1-infected patients who had a SVR and in 85 non-responders and 64 relapsers. A significantly increased risk of having a null virological response was observed in patients carrying at least one A allele at positions -308 [odds ratios (OR) = 2.58, 95% confidence intervals (CI) = 1.44-4.63, p = 0.001] or -238 (OR = 7.33, 95% CI = 3.59-14.93, p < 0.001) in the TNF promoter. The risk of relapsing was also elevated (-308: OR = 2.87, 95% CI = 1.51-5.44, p = 0.001; -238: OR = 4.20, 95% CI = 1.93-9.10, p < 0.001). Multiple logistic regression of TNF diplotypes showed that patients with at least two copies of the A allele had an even higher risk of having a null virological response (OR = 16.43, 95% CI = 5.70-47.34, p < 0.001) or relapsing (OR = 6.71, 95% CI = 2.18-20.66, p = 0.001). No statistically significant association was found between the other SNPs under study and anti-HCV therapy response.